NAVELBINE Side Effects

6969423-0 | Atelectasis, Hypotension, Pain In Extremity, Pulmonary Embolism, Respiratory Disorder
on Aug 16, 2010 Female patient from SWEDEN , 69 years of age, was treated with Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: atelectasis, hypotension, pain in extremity, pulmonary embolism (What is pulmonary embolism?), respiratory disorder. Navelbine dosage: . During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), INNOHEP (View Innohep Review and Innohep Label ). Patient was hospitalized.

6969422-9 | Cerebellar Syndrome, Diplopia, Neurotoxicity
Patient was taking Navelbine (View Usage). Patient had the following side effects: cerebellar syndrome, diplopia, neurotoxicity on Aug 18, 2010 from FRANCE Additional patient health information: Male patient , 51 years of age, was diagnosed with lung adenocarcinoma and. Navelbine dosage: 58 Mg Qd Iv. During the same period patient was treated with HOLOXAN, MFR: NOT SPECIFIED (5910 Mg Qd Iv) (View Holoxan, Mfr: Not Specified Review and Holoxan, Mfr: Not Specified Label ). Patient was hospitalized.

6969394-7 | Agranulocytosis, Leukopenia, Neutropenia
Adverse event was reported on Aug 20, 2010 by a Female patient taking Navelbine (View Usage) (Dosage: ) was diagnosed with breast cancer metastatic and. Location: FRANCE , 50 years of age, After Navelbine was administered, patient had the following side effects: agranulocytosis, leukopenia, neutropenia. During the same period patient was treated with HERCEPTIN (View Herceptin Review and Herceptin Label ), KALETRA (View Kaletra Review and Kaletra Label ). Patient was hospitalized.

6946624-9 | Anaemia, Leukopenia, Pneumonia, Renal Impairment
on Aug 10, 2010 Female patient from GERMANY , 68 years of age, weighting 154.3 lb, was diagnosed with non-small cell lung cancer and was treated with Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, leukopenia, pneumonia (What is pneumonia?), renal impairment. Navelbine dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), PACLITAXEL (View Paclitaxel Review and Paclitaxel Label ). Patient was hospitalized.


6942061-1 | Anaemia, Arthritis, Diarrhoea, Lung Infection Pseudomonal, Mucosal Discolouration, Neutropenia, Oral Herpes, Strangury, Urinary Incontinence
on Aug 05, 2010 Male patient from ITALY , 58 years of age, was diagnosed with lung neoplasm malignant and was treated with Navelbine (View Usage). Patient had the following side effects: anaemia, arthritis (What is arthritis?), diarrhoea, lung infection pseudomonal, mucosal discolouration, neutropenia, oral herpes, strangury, urinary incontinence (What is urinary incontinence?). Navelbine dosage: 50 Mg Qd Iv. During the same period patient was treated with CARBOPLATIN (480 Mg Qd Iv) (View Carboplatin Review and Carboplatin Label ), SOLDESAM (View Soldesam Review and Soldesam Label ), OMEPRAZOL. MFR: NOT SPECIFIED (View Omeprazol. Mfr: Not Specified Review and Omeprazol. Mfr: Not Specified Label ). Patient was hospitalized.

6887686-7 | Dermatitis Acneiform
Patient was taking Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: dermatitis acneiform on Jun 24, 2010 from ITALY Additional patient health information: Male patient , 39 years of age, . Navelbine dosage: 45 Mg Iv. During the same period patient was treated with TAXOTERE (130 Mg Iv) (View Taxotere Review and Taxotere Label ).

6865987-6 | Dizziness, Metastases To Liver
Adverse event was reported on Jul 08, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: 60 Mg Po) was diagnosed with non-small cell lung cancer and. Location: GERMANY , 74 years of age, weighting 165.3 lb, Patient experienced the following unwanted or unexpected effects: dizziness (What is dizziness?), metastases to liver. During the same period patient was treated with VINORELBINE (49 Mg Iv) (View Vinorelbine Review and Vinorelbine Label ), CARBOPLATIN (417 Mg) (View Carboplatin Review and Carboplatin Label ).

6862603-4 | Blood Bilirubin Increased, Blood Chloride Decreased, Blood Cholesterol Increased, Blood Lactate Dehydrogenase Increased, Cancer Pain, Decreased Appetite, Haematocrit Decreased, Haemoglobin Decreased, Platelet Count Decreased
on Jul 07, 2010 Female patient from JAPAN , 60 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Navelbine (View Usage). Patient had the following side effects: blood bilirubin increased, blood chloride decreased, blood cholesterol increased, blood lactate dehydrogenase increased, cancer pain, decreased appetite, haematocrit decreased, haemoglobin decreased, platelet count decreased. Navelbine dosage: 35 Mg Iv. During the same period patient was treated with DECADRON (View Decadron Review and Decadron Label ), CELECOX (View Celecox Review and Celecox Label ), PRIMPERAN. MFR: NOT SPECIFIED (View Primperan. Mfr: Not Specified Review and Primperan. Mfr: Not Specified Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ).

6862601-0 | Acute Pulmonary Oedema, Bronchitis, Cardiac Failure, Cardiomegaly
on Jul 02, 2010 Female patient from FRANCE , 65 years of age, was diagnosed with breast cancer (What is breast cancer?), acute leukaemia and was treated with Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: acute pulmonary oedema, bronchitis (What is bronchitis?), cardiac failure, cardiomegaly. Navelbine dosage: . During the same period patient was treated with TAXOTERE (View Taxotere Review and Taxotere Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ARACYTINE (View Aracytine Review and Aracytine Label ).

6844059-0 | Cerebellar Syndrome
Patient was taking Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: cerebellar syndrome on Jun 28, 2010 from FRANCE Additional patient health information: Male patient , 51 years of age, was diagnosed with lung adenocarcinoma and. Navelbine dosage: 58 Mg Qd Iv. During the same period patient was treated with HOLOXAN. MFR: NOT SPECIFIED (5910 Mg Qd Iv) (View Holoxan. Mfr: Not Specified Review and Holoxan. Mfr: Not Specified Label ). Patient was hospitalized.

6822886-3 | Chest Pain, Nausea
Adverse event was reported on Jul 06, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: 40mg Weekly Iv) . Location: UNITED STATES , 80 years of age, weighting 134.0 lb, Patient had the following side effects: chest pain (What is chest pain?), nausea (What is nausea?). During the same period patient was treated with ALOXI (View Aloxi Review and Aloxi Label ), DECADRON (View Decadron Review and Decadron Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6796386-3 | Dizziness, Metastases To Liver
on Jun 08, 2010 Male patient from GERMANY , 74 years of age, weighting 165.3 lb, was diagnosed with non-small cell lung cancer and was treated with Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: dizziness (What is dizziness?), metastases to liver. Navelbine dosage: 60 Mg Po. During the same period patient was treated with VINORELBINE (49 Mg Iv) (View Vinorelbine Review and Vinorelbine Label ), CARBOPLATIN (417 Mg) (View Carboplatin Review and Carboplatin Label ).

6796385-1 | Blood Alkaline Phosphatase Increased, Blood Glucose Decreased, Blood Magnesium Increased, Fatigue, Haematocrit Decreased, Haemoglobin Decreased, Hypophagia, Organising Pneumonia, Pyrexia
on Jun 07, 2010 Male patient from JAPAN , 67 years of age, was diagnosed with squamous cell carcinoma and was treated with Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: blood alkaline phosphatase increased, blood glucose decreased, blood magnesium increased, fatigue, haematocrit decreased, haemoglobin decreased, hypophagia, organising pneumonia, pyrexia. Navelbine dosage: 20 Mg/m2 Iv. During the same period patient was treated with DE 766 (200 Mg Iv) (View De-766 Review and De-766 Label ), CISPLATIN (80 Mg/m2 Iv) (View Cisplatin Review and Cisplatin Label ), MAGLAX (View Maglax Review and Maglax Label ), AMBROXOL (View Ambroxol Review and Ambroxol Label ), MYSLEE (View Myslee Review and Myslee Label ). Patient was hospitalized.

6760314-7 | Blood Culture Positive, Chromaturia, Diverticulitis, Enterovesical Fistula, Pyrexia, Staphylococcal Infection
Patient was taking Navelbine (View Usage). Patient had the following side effects: blood culture positive, chromaturia, diverticulitis, enterovesical fistula, pyrexia, staphylococcal infection (What is staphylococcal infection?) on May 20, 2010 from ITALY Additional patient health information: Female patient , 69 years of age, was diagnosed with breast cancer (What is breast cancer?) and. Navelbine dosage: 38.29 Mg Iv. During the same period patient was treated with FLUOROURACIL (3064 Mg) (View Fluorouracil Review and Fluorouracil Label ), DELTACORTENE (View Deltacortene Review and Deltacortene Label ), ARTHROTEC (View Arthrotec Review and Arthrotec Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ), LYRICA (View Lyrica Review and Lyrica Label ). Patient was hospitalized.

6760311-1 | Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Blood Chloride Decreased, Blood Lactate Dehydrogenase Increased, Blood Urea Increased, C-reactive Protein Increased, Condition Aggravated, Gamma-glutamyltransferase Increased, Haematocrit Decreased
Adverse event was reported on May 21, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: 35 Mg Iv) was diagnosed with lung neoplasm malignant and. Location: JAPAN , 61 years of age, After Navelbine was administered, patient had the following side effects: blood alkaline phosphatase increased, blood bilirubin increased, blood chloride decreased, blood lactate dehydrogenase increased, blood urea increased, c-reactive protein increased, condition aggravated, gamma-glutamyltransferase increased, haematocrit decreased. During the same period patient was treated with CARBOPLATIN (350 Mg Iv) (View Carboplatin Review and Carboplatin Label ), NORVASC (View Norvasc Review and Norvasc Label ), NU LOTAN (View Nu-lotan Review and Nu-lotan Label ), FLIVAS (View Flivas Review and Flivas Label ), GASTER D (View Gaster D Review and Gaster D Label ), LIPIDIL (View Lipidil Review and Lipidil Label ), PIRESPA (View Pirespa Review and Pirespa Label ), NEORAL (View Neoral Review and Neoral Label ).

6749729-0 | Asthenia, Dizziness, Nausea, Platelet Count Decreased, Pulse Pressure Decreased, White Blood Cell Count Decreased
on May 13, 2010 Male patient from JAPAN , 57 years of age, was treated with Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, dizziness (What is dizziness?), nausea (What is nausea?), platelet count decreased, pulse pressure decreased, white blood cell count decreased. Navelbine dosage: 50 Mg Iv. During the same period patient was treated with RANDA (View Randa Review and Randa Label ). Patient was hospitalized.

6749712-5 | Dizziness
on May 12, 2010 Male patient from GERMANY , 74 years of age, was diagnosed with non-small cell lung cancer and was treated with Navelbine (View Usage). Patient had the following side effects: dizziness (What is dizziness?). Navelbine dosage: . During the same period patient was treated with VINORELBINE (49 Mg Iv) (View Vinorelbine Review and Vinorelbine Label ), CARBOPLATIN (417 Mg) (View Carboplatin Review and Carboplatin Label ).

6740055-2 | Cystitis Haemorrhagic
Patient was taking Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: cystitis haemorrhagic on Mar 10, 2010 from ITALY Additional patient health information: Male patient , 29 years of age, was diagnosed with anaplastic large cell lymphoma t- and null-cell types and. Navelbine dosage: 25 Mg/m2 Unk Iv. During the same period patient was treated with IFOSFAMIDE (2500 Mg/m2 Unk Iv) (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.

6740054-0 | Blood Pressure Increased, Lacunar Infarction, Transient Ischaemic Attack
Adverse event was reported on May 11, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: 35 Mg/m2 Iv) was diagnosed with lung neoplasm malignant and. Location: ITALY , 61 years of age, Patient experienced the following unwanted or unexpected effects: blood pressure increased, lacunar infarction, transient ischaemic attack. Patient was hospitalized.

6733093-7 | Bronchopneumonia, Interstitial Lung Disease, Klebsiella Infection, Mobility Decreased, Neutropenic Sepsis, No Therapeutic Response, Traumatic Lung Injury
on May 05, 2010 Female patient from UNITED KINGDOM , 71 years of age, was diagnosed with adenocarcinoma and was treated with Navelbine (View Usage). Patient had the following side effects: bronchopneumonia, interstitial lung disease, klebsiella infection, mobility decreased, neutropenic sepsis, no therapeutic response, traumatic lung injury. Navelbine dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6701282-3 | Fatigue, Hypophagia, Pyrexia, Radiation Pneumonitis
on Apr 19, 2010 Male patient from JAPAN , 67 years of age, was treated with Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: fatigue, hypophagia, pyrexia, radiation pneumonitis. Navelbine dosage: 20 Mg/m2; Iv. During the same period patient was treated with DE 766 (200 Mg; Iv) (View De-766 Review and De-766 Label ), CISPLATIN (80 Mg/m2; Iv) (View Cisplatin Review and Cisplatin Label ), MAGLAX (View Maglax Review and Maglax Label ), MYSLEE (View Myslee Review and Myslee Label ). Patient was hospitalized.

6701281-1 | Abscess, Blood Culture Positive, Chromaturia, Diverticulitis, Enterovesical Fistula, Pyrexia, Staphylococcal Infection, Urine Odour Abnormal
Patient was taking Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: abscess (What is abscess?), blood culture positive, chromaturia, diverticulitis, enterovesical fistula, pyrexia, staphylococcal infection (What is staphylococcal infection?), urine odour abnormal on Apr 13, 2010 from ITALY Additional patient health information: Female patient , 69 years of age, was diagnosed with breast cancer (What is breast cancer?) and. Navelbine dosage: 38.29 Mg; Iv. During the same period patient was treated with FLUOROURACIL (3064 Mg;) (View Fluorouracil Review and Fluorouracil Label ), DELTACORTENE (View Deltacortene Review and Deltacortene Label ), ARTHROTEC (View Arthrotec Review and Arthrotec Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ), LYRICA (View Lyrica Review and Lyrica Label ). Patient was hospitalized.

6701247-1 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Lactate Dehydrogenase Increased, Condition Aggravated, Interstitial Lung Disease, Respiratory Failure
Adverse event was reported on Apr 13, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: 45 Mg Iv) was diagnosed with lung neoplasm malignant and. Location: JAPAN , 76 years of age, Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, condition aggravated, interstitial lung disease, respiratory failure. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ERYTHROMYCIN (View Erythromycin Review and Erythromycin Label ), MUCODYNE. MFR: NOT SPECIFIED (View Mucodyne. Mfr: Not Specified Review and Mucodyne. Mfr: Not Specified Label ). Patient was hospitalized.

6686106-5 | Cardio-respiratory Arrest, Hypophagia, Loss Of Consciousness, Myocardial Ischaemia, Platelet Count Decreased, Ventricular Fibrillation
on Mar 29, 2010 Male patient from JAPAN , 73 years of age, was treated with Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: cardio-respiratory arrest, hypophagia, loss of consciousness, myocardial ischaemia, platelet count decreased, ventricular fibrillation. Navelbine dosage: 33 Mg, Cyclical Intravenous. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ), OXINORM (ORGOTEIN) (View Oxinorm (orgotein) Review and Oxinorm (orgotein) Label ), PRIMPERAN TAB (View Primperan Tab Review and Primperan Tab Label ), NOVAMIN (PROCHLORPERAZINE) (View Novamin (prochlorperazine) Review and Novamin (prochlorperazine) Label ), MAGLAX (MAGNESIUM OXIDE) (View Maglax (magnesium Oxide) Review and Maglax (magnesium Oxide) Label ), MUCOSTA (REBAMIPIDE) (View Mucosta (rebamipide) Review and Mucosta (rebamipide) Label ), LOXONIN (LOXOPROFEN SODIUM) (View Loxonin (loxoprofen Sodium) Review and Loxonin (loxoprofen Sodium) Label ).

6685998-3 | Peripheral Ischaemia
on Mar 31, 2010 Male patient from ITALY , 54 years of age, was treated with Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: peripheral ischaemia. Navelbine dosage: . Patient was hospitalized.

6683604-5 | Asthenia, Hiccups, Vomiting
Patient was taking Navelbine (View Usage). Patient had the following side effects: asthenia, hiccups, vomiting on Mar 31, 2010 from ITALY Additional patient health information: Male patient , 63 years of age, was diagnosed with lung neoplasm malignant and. Navelbine dosage: . Patient was hospitalized.

6683546-5 | Asthenia, Dehydration, Renal Failure Acute
Adverse event was reported on Mar 31, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: ) . Location: ITALY , 73 years of age, After Navelbine was administered, patient had the following side effects: asthenia, dehydration, renal failure acute. During the same period patient was treated with PLATINEX (View Platinex Review and Platinex Label ). Patient was hospitalized.

6683545-3 | Asthenia, Dehydration, Renal Failure Acute
on Mar 31, 2010 Male patient from ITALY , 73 years of age, was treated with Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, dehydration, renal failure acute. Navelbine dosage: . During the same period patient was treated with PLATINEX (View Platinex Review and Platinex Label ). Patient was hospitalized.

6674229-6 | Malignant Neoplasm Progression
on Dec 28, 2005 Female patient from IRELAND , 48 years of age, was diagnosed with breast cancer metastatic and was treated with Navelbine (View Usage). Patient had the following side effects: malignant neoplasm progression. Navelbine dosage: 25 Mg/m2 Daily Iv. During the same period patient was treated with PREGABALIN (75 Mg Daily) (View Pregabalin Review and Pregabalin Label ), CODALAX (View Codalax Review and Codalax Label ), GLUCOPHAGE (View Glucophage Review and Glucophage Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), CIPRAMIL (View Cipramil Review and Cipramil Label ), HYDROMORPHONE HCL (View Hydromorphone Hcl Review and Hydromorphone Hcl Label ). Patient was hospitalized and became disabled.

6674227-2 | Blood Pressure Increased, Transient Ischaemic Attack
Patient was taking Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: blood pressure increased, transient ischaemic attack on Mar 12, 2010 from ITALY Additional patient health information: Male patient , 61 years of age, was diagnosed with lung neoplasm malignant and. Navelbine dosage: 35 Mg/m2, Iv. Patient was hospitalized.

6668739-5 | Bacterial Sepsis, Blood Culture Positive, Cholecystitis Acute, Escherichia Infection, Klebsiella Infection, Leukopenia
Adverse event was reported on Mar 19, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: 25 Mg/m2 Iv) was diagnosed with lymphoma (What is lymphoma?) and. Location: ITALY , 83 years of age, Patient experienced the following unwanted or unexpected effects: bacterial sepsis, blood culture positive, cholecystitis acute, escherichia infection, klebsiella infection, leukopenia. During the same period patient was treated with DELTACORTENE (View Deltacortene Review and Deltacortene Label ). Patient was hospitalized.

6668738-3 | Cardio-respiratory Arrest, Loss Of Consciousness, Ventricular Fibrillation
on Mar 11, 2010 Male patient from JAPAN , 73 years of age, was treated with Navelbine (View Usage). Patient had the following side effects: cardio-respiratory arrest, loss of consciousness, ventricular fibrillation. Navelbine dosage: 33 Mg Iv. During the same period patient was treated with BRIPLATIN (View Briplatin Review and Briplatin Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ), PRIMPERAN (View Primperan Review and Primperan Label ), OXINORM (View Oxinorm Review and Oxinorm Label ), PROCHLORPERAZINE (View Prochlorperazine Review and Prochlorperazine Label ), MAGLAX (View Maglax Review and Maglax Label ), MUCOSTA (View Mucosta Review and Mucosta Label ), LOXONIN (View Loxonin Review and Loxonin Label ).

6668728-0 | Pain, Paraesthesia, Skin Exfoliation, Skin Fissures
on Mar 23, 2010 Female patient from JAPAN , 68 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: pain (What is pain?), paraesthesia, skin exfoliation, skin fissures. Navelbine dosage: 36.5 Mg Unk Iv. During the same period patient was treated with HERCEPTIN (100 Mg 1 X Wk Iv) (View Herceptin Review and Herceptin Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ).

6660491-2 | Blood Pressure Increased, Transient Ischaemic Attack
Patient was taking Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure increased, transient ischaemic attack on Mar 12, 2010 from ITALY Additional patient health information: Male patient , 61 years of age, was diagnosed with lung neoplasm malignant and. Navelbine dosage: 35 Mg/m2 Iv. Patient was hospitalized.

6660477-8 | Asthenia, Bacterial Sepsis, Blood Culture Positive, Cholecystitis Acute, Escherichia Infection, Klebsiella Infection, Leukopenia
Adverse event was reported on Mar 19, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: 25 Mg/m2 Iv) was diagnosed with lymphoma (What is lymphoma?) and. Location: ITALY , 83 years of age, Patient had the following side effects: asthenia, bacterial sepsis, blood culture positive, cholecystitis acute, escherichia infection, klebsiella infection, leukopenia. During the same period patient was treated with DELTACORTENE. MFR: NOT SPECIFIED (View Deltacortene. Mfr: Not Specified Review and Deltacortene. Mfr: Not Specified Label ). Patient was hospitalized.

6659703-0 | Cystitis Haemorrhagic
on Mar 10, 2010 Male patient from ITALY , 29 years of age, was diagnosed with anaplastic large cell lymphoma t- and null-cell types and was treated with Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: cystitis haemorrhagic. Navelbine dosage: 25 Mg/m2 Iv. During the same period patient was treated with IFOSFAMIDE (250 Mg/m2 Iv) (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.

6650078-X | Acute Respiratory Distress Syndrome, Candidiasis, Convulsion, Cyanosis, Epilepsy, Febrile Bone Marrow Aplasia, Flatulence, Haematuria
on Feb 19, 2010 Male patient from FRANCE , child 6 years of age, weighting 52.91 lb, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: acute respiratory distress syndrome, candidiasis, convulsion, cyanosis, epilepsy (What is epilepsy?), febrile bone marrow aplasia, flatulence, haematuria. Navelbine dosage: 135 Mg Qd Iv. During the same period patient was treated with IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), MITOGUAZONE (View Mitoguazone Review and Mitoguazone Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ), NALBUPHINE (View Nalbuphine Review and Nalbuphine Label ), PHLOROGLUCINOL (View Phloroglucinol Review and Phloroglucinol Label ), SPASFON (View Spasfon Review and Spasfon Label ). Patient was hospitalized.

6648342-3 | Bronchospasm, Cyanosis, Dyspnoea
Patient was taking Navelbine (View Usage). Patient had the following side effects: bronchospasm, cyanosis, dyspnoea on May 12, 2009 from FRANCE Additional patient health information: Male patient , 79 years of age, was diagnosed with lung cancer metastatic and. Navelbine dosage: 45 Mg Iv. Patient was hospitalized.

6639801-8 | Pancytopenia, Pyrexia
Adverse event was reported on Mar 02, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: 42 Mg Iv) was diagnosed with non-small cell lung cancer stage iv and. Location: ITALY , 62 years of age, After Navelbine was administered, patient had the following side effects: pancytopenia, pyrexia. During the same period patient was treated with PRONTO PLAMINE (100 Mg Iv) (View Pronto Plamine Review and Pronto Plamine Label ), ZOFRAN (View Zofran Review and Zofran Label ), LASIX (View Lasix Review and Lasix Label ), SOLDESAM (View Soldesam Review and Soldesam Label ).

6637414-5 | Pulmonary Embolism
on Feb 26, 2010 Male patient from UNITED KINGDOM , 42 years of age, was diagnosed with non-small cell lung cancer and was treated with Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary embolism (What is pulmonary embolism?). Navelbine dosage: 42 Mg Iv. During the same period patient was treated with CISPLATIN (126 Mg) (View Cisplatin Review and Cisplatin Label ).

6637413-3 | Pulmonary Embolism
on Feb 26, 2010 Male patient from UNITED KINGDOM , 64 years of age, was diagnosed with non-small cell lung cancer and was treated with Navelbine (View Usage). Patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). Navelbine dosage: 50 Mg Iv. During the same period patient was treated with CISPLATIN (150 Mg) (View Cisplatin Review and Cisplatin Label ).

6637412-1 | Lower Respiratory Tract Infection, Neutropenic Sepsis
Patient was taking Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: lower respiratory tract infection, neutropenic sepsis on Feb 26, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 50 years of age, was diagnosed with non-small cell lung cancer and. Navelbine dosage: 42 Mg Iv. During the same period patient was treated with CISPLATIN (125 Mg) (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6637411-X | Decreased Appetite, Dehydration, Neutropenia, Vomiting
Adverse event was reported on Feb 25, 2010 by a Male patient taking Navelbine (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer and. Location: UNITED KINGDOM , 52 years of age, Patient experienced the following unwanted or unexpected effects: decreased appetite, dehydration, neutropenia, vomiting. During the same period patient was treated with VINORELBINE (View Vinorelbine Review and Vinorelbine Label ), DOMPERIDONE (View Domperidone Review and Domperidone Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ). Patient was hospitalized.

6624770-7 | Accidental Overdose, Acute Respiratory Distress Syndrome, Candida Sepsis, Convulsion, Depressed Level Of Consciousness, Disorientation, Febrile Bone Marrow Aplasia, Ileus
on Feb 19, 2010 Male patient from FRANCE , child 6 years of age, weighting 52.91 lb, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Navelbine (View Usage). Patient had the following side effects: accidental overdose, acute respiratory distress syndrome, candida sepsis, convulsion, depressed level of consciousness, disorientation, febrile bone marrow aplasia, ileus. Navelbine dosage: 135 Mg Qd Iv. During the same period patient was treated with IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), MITOGUAZONE (View Mitoguazone Review and Mitoguazone Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6624734-3 | Anaphylactic Shock, Bronchospasm, Cyanosis, Platelet Count Decreased
on Feb 19, 2010 Male patient from JAPAN , 70 years of age, was treated with Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: anaphylactic shock, bronchospasm, cyanosis, platelet count decreased. Navelbine dosage: 37 Mg Iv. During the same period patient was treated with GEMZAR (1500 Mg Iv) (View Gemzar Review and Gemzar Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), DECADRON (View Decadron Review and Decadron Label ).

6624639-8 | Alanine Aminotransferase Increased, Asthenia, Cholecystitis Acute, Escherichia Sepsis, Irritability, Klebsiella Sepsis, Leukopenia, Lymphadenopathy
Patient was taking Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, asthenia, cholecystitis acute, escherichia sepsis, irritability, klebsiella sepsis, leukopenia, lymphadenopathy on Feb 22, 2010 from ITALY Additional patient health information: Male patient , 83 years of age, was diagnosed with lymphoma (What is lymphoma?) and. Navelbine dosage: 25 Mg/m2 Iv. During the same period patient was treated with DELTACORTENE (View Deltacortene Review and Deltacortene Label ). Patient was hospitalized.

6622265-8 | Bradycardia, Dehydration, Diarrhoea, Hypokalaemia, Syncope
Adverse event was reported on Feb 22, 2010 by a Female patient taking Navelbine (View Usage) (Dosage: ) was diagnosed with breast cancer metastatic and. Location: UNITED STATES , 56 years of age, Patient had the following side effects: bradycardia, dehydration, diarrhoea, hypokalaemia, syncope. During the same period patient was treated with NERATINIB (240 Mg Qd Po) (View Neratinib Review and Neratinib Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), LOMOTIL. MFR: NOT SPECIFIED (View Lomotil. Mfr: Not Specified Review and Lomotil. Mfr: Not Specified Label ), AMBIEN (View Ambien Review and Ambien Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), KLONOPIN (View Klonopin Review and Klonopin Label ), KEFLEX (View Keflex Review and Keflex Label ), XYLOCAINE. MFR: NOT SPECIFIED (View Xylocaine. Mfr: Not Specified Review and Xylocaine. Mfr: Not Specified Label ). Patient was hospitalized.

6613513-9 | Cardiogenic Shock, Left Ventricular Failure, Pulmonary Oedema
on Feb 10, 2010 Male patient from GERMANY , 76 years of age, weighting 165.3 lb, was diagnosed with non-small cell lung cancer and was treated with Navelbine (View Usage). After Navelbine was administered, patient had the following side effects: cardiogenic shock, left ventricular failure, pulmonary oedema. Navelbine dosage: 37 Mg Iv. During the same period patient was treated with CARBOPLATIN (270 Mg Iv) (View Carboplatin Review and Carboplatin Label ).

6613187-7 | Bradycardia, Chest Pain, Circulatory Collapse, Diabetic Complication, Hyperkalaemia, Ileus Paralytic, Metabolic Disorder, Neutropenia, Pancreatitis Acute
on Sep 11, 2009 Male patient from FRANCE , 62 years of age, was diagnosed with lung neoplasm malignant and was treated with Navelbine (View Usage). Patient experienced the following unwanted or unexpected effects: bradycardia, chest pain (What is chest pain?), circulatory collapse, diabetic complication, hyperkalaemia, ileus paralytic, metabolic disorder (What is metabolic disorder?), neutropenia, pancreatitis acute. Navelbine dosage: 60 Mg Iv. During the same period patient was treated with CISPLATIN (160 Mg Iv) (View Cisplatin Review and Cisplatin Label ), EMEND (125 Mg Qd Po) (View Emend Review and Emend Label ), ZOPHREN (8 Mg Bid Iv) (View Zophren Review and Zophren Label ).

6610172-6 | Blood Sodium Decreased, Haemoglobin Decreased, Interstitial Lung Disease, Respiratory Failure
Patient was taking Navelbine (View Usage). Patient had the following side effects: blood sodium decreased, haemoglobin decreased, interstitial lung disease, respiratory failure on Feb 09, 2010 from JAPAN Additional patient health information: Male patient , 76 years of age, was diagnosed with lung neoplasm malignant and. Navelbine dosage: 45 Mg Iv. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ERYTHROMYCIN (View Erythromycin Review and Erythromycin Label ), MUCODYNE. MFR: NOT SPECIFIED (View Mucodyne. Mfr: Not Specified Review and Mucodyne. Mfr: Not Specified Label ). Patient was hospitalized.